Related Experiment Video

Updated: Sep 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

[The effect of lovastatin in the treatment of primary hypercholesterolemia]

J M Chi1, L S Li, M Z Sun

  • 1Department of Internal Medicine, Beijing Hospital.

Zhonghua Nei Ke Za Zhi
|January 1, 1992
PubMed

Insights

Lovastatin effectively lowers total cholesterol, LDL-C, and Apo-B in patients with primary hypercholesterolemia. This HMG-CoA reductase inhibitor demonstrated significant reductions in key lipid and apolipoprotein levels over a 3-month treatment period.

Area of Science:

  • Cardiovascular Pharmacology
  • Metabolic Disorders
  • Lipid Metabolism

Context:

  • Primary hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • Current lipid-lowering therapies aim to reduce atherogenic lipoproteins.
  • Understanding the efficacy of HMG-CoA reductase inhibitors is crucial for managing dyslipidemia.

Purpose:

  • To evaluate the efficacy of Lovastatin in reducing serum lipids and apolipoproteins in patients with primary hypercholesterolemia.
  • To assess the safety and tolerability of Lovastatin treatment.

Summary:

  • Lovastatin treatment significantly reduced mean serum total cholesterol (TC) by 31.5%, LDL-C by 39.8%, Apo-B by 27.3%, and the TC/HDL-C ratio by 35.9%.
  • While a reduction in triglycerides (TG) and an increase in HDL-C were observed, these changes were not statistically significant.
  • The drug was generally well-tolerated, with minor gastrointestinal discomfort and transient enzyme elevations reported in a few patients.

Impact:

  • Lovastatin demonstrates significant efficacy in lowering key atherogenic lipid and apolipoprotein markers.
  • The findings support Lovastatin as an effective therapeutic option for managing primary hypercholesterolemia.
  • The favorable safety profile suggests good patient compliance and potential for long-term use.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...